^
Association details:
Biomarker:BCL6 translocation
Cancer:Non-Hodgkin’s Lymphoma
Drug Class:T-lymphocyte cell therapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Published date:
11/01/2018
Excerpt:
Between March 2016 and January 2018, a total of 89 eligibility pts completed CAR-22/19 "cocktail" infusion and were included for analysis. Of 89 pts (median age 36 years; range, 9-71), 51 had refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and 38 had R/R B-cell non-Hodgkin lymphoma (B-NHL)....At a minimum follow-up of 3 months, the overall response rate (ORR) and CR rate in 36 evaluable B-NHL pts was 72.2% and 50%, respectively....Of the 9 pts with MYC translocation, 8 had a response and 7 maintained their responses with a median follow-up of 10.1 months, including all the 4 pts with "double-hit" lymphoma (concurrently carrying MYC and BCL2 or BCL6 translocations).
DOI:
https://doi.org/10.1182/blood-2018-99-113714